CN114133367A - 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 - Google Patents
一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 Download PDFInfo
- Publication number
- CN114133367A CN114133367A CN202111209332.7A CN202111209332A CN114133367A CN 114133367 A CN114133367 A CN 114133367A CN 202111209332 A CN202111209332 A CN 202111209332A CN 114133367 A CN114133367 A CN 114133367A
- Authority
- CN
- China
- Prior art keywords
- cdcl
- nmr
- dihydropyrone
- formula
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 sulphoxide imino dihydropyrone derivatives Chemical class 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 230000003197 catalytic effect Effects 0.000 claims abstract description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims abstract description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- OKIJSNGRQAOIGZ-UHFFFAOYSA-N Butopyronoxyl Chemical class CCCCOC(=O)C1=CC(=O)CC(C)(C)O1 OKIJSNGRQAOIGZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- 239000003054 catalyst Substances 0.000 abstract description 6
- 229910000510 noble metal Inorganic materials 0.000 abstract description 3
- 125000000524 functional group Chemical group 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 142
- 239000000203 mixture Substances 0.000 description 52
- 238000005160 1H NMR spectroscopy Methods 0.000 description 46
- 238000005259 measurement Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 26
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 25
- 238000004896 high resolution mass spectrometry Methods 0.000 description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 24
- 239000007788 liquid Substances 0.000 description 24
- GVDIMCNBJVLTNN-UHFFFAOYSA-N 6-hydroxy-4H-pyran-3-one Chemical compound OC1=CCC(=O)CO1 GVDIMCNBJVLTNN-UHFFFAOYSA-N 0.000 description 15
- KNPJTNDEHOFWKA-UHFFFAOYSA-N imino-oxo-diphenyl-$l^{6}-sulfane Chemical compound C=1C=CC=CC=1S(=O)(=N)C1=CC=CC=C1 KNPJTNDEHOFWKA-UHFFFAOYSA-N 0.000 description 11
- 229940124530 sulfonamide Drugs 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- 125000005555 sulfoximide group Chemical group 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- PLYSJDAYJMFETG-UHFFFAOYSA-N 2-hydroxy-6-methyl-2h-pyran-5-one Chemical compound CC1OC(O)C=CC1=O PLYSJDAYJMFETG-UHFFFAOYSA-N 0.000 description 1
- NFGZGSGCIIIPPH-UHFFFAOYSA-N 2-hydroxy-6-phenyl-2H-pyran-5-one Chemical compound O=C1C=CC(O)OC1C1=CC=CC=C1 NFGZGSGCIIIPPH-UHFFFAOYSA-N 0.000 description 1
- NELPFHSGUHHZSX-UHFFFAOYSA-N 2-hydroxy-6-propan-2-yl-2H-pyran-5-one Chemical compound CC(C)C1OC(O)C=CC1=O NELPFHSGUHHZSX-UHFFFAOYSA-N 0.000 description 1
- MWVHKARYHPMRNQ-UHFFFAOYSA-N 2-hydroxy-6-propyl-2H-pyran-5-one Chemical compound CCCC1OC(O)C=CC1=O MWVHKARYHPMRNQ-UHFFFAOYSA-N 0.000 description 1
- VIIIJFZJKFXOGG-UHFFFAOYSA-N 3-methylchromen-2-one Chemical compound C1=CC=C2OC(=O)C(C)=CC2=C1 VIIIJFZJKFXOGG-UHFFFAOYSA-N 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- YUTAFCIWIJWQIX-UHFFFAOYSA-N 6-ethyl-2-hydroxy-2h-pyran-5-one Chemical compound CCC1OC(O)C=CC1=O YUTAFCIWIJWQIX-UHFFFAOYSA-N 0.000 description 1
- 238000006685 Achmatowicz rearrangement reaction Methods 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000005905 alkynylation reaction Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- PQEQYIQDYKTOFZ-UHFFFAOYSA-N dibenzyl-imino-oxo-$l^{6}-sulfane Chemical compound C=1C=CC=CC=1CS(=O)(=N)CC1=CC=CC=C1 PQEQYIQDYKTOFZ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 238000006886 vinylation reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0255—Phosphorus containing compounds
- B01J31/0257—Phosphorus acids or phosphorus acid esters
- B01J31/0258—Phosphoric acid mono-, di- or triesters ((RO)(R'O)2P=O), i.e. R= C, R'= C, H
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明应用于有机合成技术领域,是一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法。在有机溶剂中,在(PhO)2P(O)OH催化作用下,亚砜亚胺化合物与二氢吡喃酮化合物的发生亲核取代反应制备亚砜亚胺基二氢吡喃酮类衍生物。该方法条件温和、操作简单、官能团兼容性好,避免了传统方法中使用的贵金属催化剂。
Description
技术领域
本发明应用于有机合成技术领域,是一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法。
背景技术
亚砜亚胺类化合物是砜基的一种含氮类似物,由于其独特的结构与性质,自从被发现以来一直备受关注,并展示出广泛的生物活性(Eur.J.Med.Chem.2017,126,225–245)。此外,亚砜亚胺也被用作试剂(Acc.Chem.Res.1973,6,341–347)、手性助剂(J.Am.Chem.Soc.1995,117,2453–2466)、手性配体(J.Am.Chem.Soc.2001,123,3830–3831)、有机催化剂(J.Org.Chem.2012,8,1443–1451)等。通过亚砜亚胺能够实现各种转化反应,包括芳基化、烷基化、乙烯基化、炔基化和其他反应(Asian J.Org.Chem.2020,9,2035-2082及Chem.Rec.2021,21,396-416)。但是,目前还没有合成亚砜亚胺基二氢吡喃酮的方法被报道出来。
含有N-糖苷键结构的氮苷糖具有广泛的药理作用,是一些抗生素、抗肿瘤药物和抗病毒药物等的重要母环结构(Chem.Rev.1996,96,683及Synlett.2009,07,1154-1156及Synthesis.2009,4143)。使用Achmatowicz重排反应的产物二氢吡喃酮为糖基供体的“denovo”从头合成糖的策略已成为合成糖苷化合物的重要方法之一(Chem.Asian J.2017,12,1027-1042)。2006年,O’Doherty等人以6-氯嘌呤和Boc保护的二氢吡喃酮为原料,通过形成π-烯丙基钯中间体,实现了高对映选择性及非对映选择性合成氮苷糖类衍生物(Org.Lett.2006,8,293–296)。2020年,申请人以Boc保护的二氢吡喃酮为供体,甲基香豆素为受体,通过钯催化烯丙基-烯丙基偶联反应,在温和条件下实现了高对映选择性及非对映选择性合成碳苷糖类衍生物(Adv.Synth.Catal.2021,363,846-850)。除了钯催化剂以外,铱也能够催化类似的反应。2018年,申请人在温和的条件下,以羟基无保护的二氢吡喃酮为供体,通过形成π-烯丙基铱中间体实现高区域选择性和非对映选择性合成氮杂糖类衍生物(J.Org.Chem.2018,83,12822-12830)。但是,上述方法多是使用了昂贵的金属催化剂来用于催化。因此,发展一种无金属催化的de novo合成糖苷类化合物的新策略是非常重要的,尤其是对金属残留指标要求较高的制药行业中。
发明内容
本发明的目的是克服现有技术中的不足,本发明提出了一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法,该方法条件温和、操作简单、官能团兼容性好,避免了传统方法中使用的贵金属催化剂,包括以亚砜亚胺和二氢吡喃酮为原料的制备亚砜亚胺基二氢吡喃酮类衍生物的方法。
本发明是通过如下技术方案实现上述目的的,一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法,
在有机溶剂中,在(PhO)2P(O)OH催化作用下,式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的发生亲核取代反应制备式III所示亚砜亚胺基二氢吡喃酮类衍生物,反应式如下:
其中,R1和R2独立地为烷基或芳基,R3为氢、烷基或芳基;I为亚砜亚胺类化合物,Ⅱ为二氢吡喃酮类化合物;
优选地,R1、R2和R3中烷基为C1-C6的烷基、C3-C8的环烷基。
优选地,所述R1、R2和R3中芳基为苯基或任选位置被Ra取代的苯基;所述Ra为C1-C6的烷基、C1-C6的烷氧基、卤素;
优选地,反应温度为0-60℃,优选为20-30℃,反应时间为12-72h,制备得到收率不低于44%的亚砜亚胺基二氢吡喃酮类衍生物。
优选地,所述式III所示亚砜亚胺基二氢吡喃酮类衍生物为
优选地,式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的摩尔比为1:1-10:1,优选为2:1。
优选地,所述的(PhO)2P(O)OH的用量为二氢吡喃酮的20mol%。
优选地,所述的有机溶剂为乙腈、甲苯、氯仿、二氯甲烷、1,2-二氯乙烷、四氢呋喃、丙酮中的一种或两种以上混合,优选溶剂为氯仿,或二氯甲烷。
本发明的有益效果:
1)本发明中亚砜亚胺和二氢吡喃酮类化合物的布朗斯特酸催化偶联制备方法反应条件温和,产物收率不低于44%
2)本发明方法的原料简单易得,底物范围广,条件温和,反应易操作,产率中等到良好。
3)本发明方法避免了传统上使用的贵金属钯、铱等催化剂,进一步丰富了“denovo”从头合成糖苷类化合物的策略,可为设计与合成氮苷糖类化合物提供方法学基础和指导,制备得到的亚砜亚胺基二氢吡喃酮类衍生物具有潜在的生理活性。
具体实施方式
实施例1:
6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到无色液体产物43mg,产率68%。
1H NMR(400MHz,CDCl3)δ8.00(dd,J=9.7,7.8Hz,4H),7.58–7.48(m,6H),7.00(dd,J=10.2,3.3Hz,1H),6.09(d,J=10.3Hz,1H),5.46(d,J=2.8Hz,1H),4.69(d,J=16.6Hz,1H),4.05(d,J=16.6Hz,1H).13C NMR(101MHz,CDCl3)δ195.40,150.50,140.34,139.97,133.06,133.03,129.38,129.33,128.62,128.18,125.80,78.35,67.52.高分辨质谱(ESI,m/z):[M+H]+计算值:C17H16NSO3,314.0845;测量值:314.0849.
实施例2:
2-甲基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于二氯乙烷(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-甲基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到无色液体产物42mg,产率64%,dr=2:1。
主要异构体:1H NMR(600MHz,CDCl3)δ8.00–7.97(m,4H),7.52–7.47(m,6H),6.93(dd,J=10.1,3.7Hz,1H),6.01(d,J=10.1Hz,1H),5.51(d,J=3.1Hz,1H),4.83(q,J=6.7Hz,1H),1.24(d,J=6.8Hz,3H).
次要异构体:1H NMR(600MHz,CDCl3)δ8.07–8.02(m,4H),7.57–7.52(m,6H),7.04(dd,J=10.1,1.2Hz,1H),6.08(dd,J=10.1,1.7Hz,1H),5.54(d,J=1.3Hz,1H),4.04–3.99(m,1H),1.31(d,J=6.6Hz,3H).
13C NMR(151MHz,CDCl3)δ197.89,196.85,152.65,149.17,140.86,140.09,132.96,132.91,132.89,129.31,129.26,129.21,129.07,128.89,128.49,128.10,126.94,125.04,124.79,80.65,77.58,75.92,70.65,15.65,15.14.高分辨质谱(ESI,m/z):[M+H]+计算值:328.1001;测量值:测量值:328.0999.13C NMR和高分辨质谱是针对两种异构体混合物的表征结果,其余实施例相同(针对存在dr值的实施例)。实施例3:
2-乙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于二氯甲烷(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-乙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物48mg,产率70%,dr=2:1。
主要异构体:1H NMR(600MHz,CDCl3)δ8.08–7.96(m,4H),7.56–7.45(m,6H),6.94(dd,J=10.1,3.6Hz,1H),6.01(d,J=10.1Hz,1H),5.51(d,J=2.9Hz,1H),4.64(dd,J=8.0,3.9Hz,1H),1.92–1.59(m,2H),0.90(t,J=7.4Hz,3H).
次要异构体:1H NMR(600MHz,CDCl3)δ8.08–7.96(m,4H),7.56–7.45(m,6H),7.05(dd,J=10.1,1.2Hz,1H),6.08(dd,J=10.1,1.8Hz,1H),5.56(d,J=1.3Hz,1H),3.78–3.76(m,1H),1.92–1.59(m,2H),0.78(t,J=7.4Hz,3H).
13C NMR(151MHz,CDCl3)δ197.58,196.46,152.75,149.36,140.65,140.10,132.93,132.85,129.31,129.27,129.18,129.07,128.93,128.69,128.11,127.96,127.38,125.43,80.83,80.70,77.30,75.73,22.98,22.89,9.62.高分辨质谱(ESI,m/z):[M+H]+理论值:342.1158;测量值:342.1162.
实施例4:
2-丙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-丙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物45mg,产率63%,dr=1.5:1。
主要异构体:1H NMR(400MHz,CDCl3)δ8.07–7.96(m,4H),7.57–7.43(m,6H),6.93(dd,J=10.1,3.6Hz,1H),6.01(d,J=10.1Hz,1H),5.49(d,J=3.6Hz,1H),4.70(dd,J=8.7,3.7Hz,1H),1.89–1.52(m,2H),1.43–1.12(m,2H),0.91(t,J=7.4Hz,3H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.07–7.96(m,4H),7.57–7.43(m,6H),7.05(d,J=10.2Hz,1H),6.08(dd,J=10.1,1.8Hz,1H),5.55(s,1H),3.83(dd,J=9.1,2.0Hz,1H),1.89–1.52(m,2H),1.43–1.12(m,2H),0.78(t,J=7.4Hz,3H).
13C NMR(151MHz,CDCl3)δ197.71,196.67,152.71,149.33,141.07,140.55,140.05,132.93,132.85,132.78,129.32,129.27,129.17,129.05,128.92,128.72,128.14,127.97,127.36,125.37,124.79,80.66,79.26,77.30,74.56,31.62,31.59,18.46,18.19,13.93,13.67.高分辨质谱(ESI,m/z):[M+H]+理论值:356.1314;测量值:测量值:356.1319.实施例5:
2-异丙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于THF(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-异丙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物48mg,产率68%,dr=2:1。
主要异构体:1H NMR(600MHz,CDCl3)δ8.07–7.95(m,4H),7.55–7.45(m,6H),6.94(dd,J=10.1,3.7Hz,1H),6.01(d,J=10.0Hz,1H),5.52(d,J=3.1Hz,1H),4.56(d,J=3.4Hz,1H),2.35(dddd,J=16.5,9.6,8.5,4.8Hz,1H),1.00–0.63(m,6H).
次要异构体:1H NMR(600MHz,CDCl3)δ8.07–7.95(m,4H),7.55–7.45(m,6H),7.11–7.05(m,1H),6.08(dd,J=10.1,1.6Hz,1H),5.61(d,J=1.0Hz,1H),3.68(s,1H),2.35(dddd,J=16.5,9.6,8.5,4.8Hz,1H),1.00–0.63(m,6H).
13C NMR(151MHz,CDCl3)δ197.69,196.55,152.87,149.29,141.86,141.06,140.62,140.20,132.93,132.90,132.75,132.68,129.29,129.27,129.14,129.03,128.87,128.81,128.10,127.80,125.83,83.83,80.93,78.89,77.19,28.51,28.09,19.09,16.54,16.08.高分辨质谱(ESI,m/z):[M+H]+理论值:356.1314;测量值:测量值:356.1317.
实施例6:
2-环丙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-环丙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物47mg,产率66%,dr=2:1。
主要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.91(m,4H),7.58–7.42(m,6H),6.93(dd,J=10.1,3.5Hz,1H),6.02(dd,J=10.1,1.0Hz,1H),5.53–5.50(m,1H),4.14(d,J=7.6Hz,1H),1.33–1.07(m,1H),0.64–0.10(m,4H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.91(m,4H),7.58–7.42(m,6H),7.02(dd,J=10.1,1.5Hz,1H),6.09(dd,J=10.1,2.0Hz,1H),5.53–5.50(m,1H),4.14(d,J=7.6Hz,1H),1.33–1.07(m,1H),0.64–0.10(m,4H).
13C NMR(151MHz,CDCl3)δ195.82,195.04,151.32,148.25,139.95,139.50,139.43,138.69,131.91,131.84,131.78,128.26,128.19,128.09,128.01,127.86,127.57,127.06,126.84,126.81,126.21,124.46,80.71,79.46,76.73,76.69,10.07,9.82,1.99,1.46,0.03,-0.01.高分辨质谱(ESI,m/z):[M+H]+理论值:354.1158;测量值:测量值:354.1161.实施例7:
2-环戊基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-环戊基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物45mg,产率59%,dr=1.5:1。
主要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.95(m,4H),7.56–7.46(m,6H),6.92(dd,J=10.1,3.5Hz,1H),6.00(dd,J=10.1,1.0Hz,1H),5.51(dd,J=3.5,0.9Hz,1H),4.61(d,J=5.5Hz,1H),2.54–2.38(m,1H),1.74–1.17(m,8H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.95(m,4H),7.56–7.46(m,6H),7.05(dd,J=10.1,1.3Hz,1H),6.07(dd,J=10.1,2.0Hz,1H),5.61(dd,J=3.3,1.6Hz,1H),3.81(dd,J=4.7,1.5Hz,1H),2.54–2.38(m,1H),1.74–1.17(m,8H).
13C NMR(151MHz,CDCl3)δ197.72,196.70,152.55,149.20,141.64,140.91,140.52,140.06,132.94,132.90,132.76,132.65,129.30,129.27,129.14,129.04,128.86,128.81,128.14,127.81,125.78,124.79,81.84,80.96,77.48,77.39,39.32,39.27,28.71,28.55,27.23,26.68,25.83,25.67,25.53,25.50.高分辨质谱(ESI,m/z):[M+H]+理论值:382.1471;测量值:382.1473.
实施例8:
2-苯基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-苯基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物56mg,产率72%,dr=3:1。
主要异构体:1H NMR(400MHz,CDCl3)δ8.05–7.95(m,4H),7.56–7.40(m,6H),7.29–7.22(m,5H),7.03(dd,J=10.2,3.4Hz,1H),6.15(dd,J=10.2,1.1Hz,1H),5.71(s,1H),5.59(dd,J=3.3,1.0Hz,1H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.05–7.95(m,4H),7.56–7.40(m,6H),7.29–7.22(m,5H),7.19(dd,J=10.2,1.4Hz,1H),6.21(dd,J=10.2,1.9Hz,1H),5.80(dd,J=3.3,1.6Hz,1H),4.94(d,J=1.2Hz,1H).
13C NMR(151MHz,CDCl3)δ195.28,194.28,152.70,150.06,141.19,140.92,140.37,140.00,135.69,135.57,133.03,132.95,132.85,132.78,129.34,129.27,129.20,129.11,128.72,128.19,128.14,128.09,127.99,127.93,127.91,127.84,127.66,127.58,125.77,124.81,81.50,81.49,77.72,77.52.高分辨质谱(ESI,m/z):[M+H]+calcd forC23H20NO3S,390.1158;测量值:390.1158.
实施例9:
2-(对甲苯基)-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-(对甲苯基)-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物63mg,产率78%,dr=3:1。
主要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.99(m,4H),7.56–7.42(m,6H),7.16–7.07(m,4H),7.03(dd,J=10.2,3.4Hz,1H),6.15(dd,J=10.1,1.1Hz,1H),5.69(s,1H),5.58(dd,J=3.3,1.1Hz,1H),2.33(d,J=3.6Hz,3H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.05–7.98(m,4H),7.56–7.42(m,6H),7.21–7.18(m,1H),7.16–7.07(m,4H),6.21(dd,J=10.2,1.9Hz,1H),5.79(dd,J=3.3,1.6Hz,1H),4.93(d,J=1.1Hz,1H),2.33(d,J=3.6Hz,3H).
13C NMR(151MHz,CDCl3)δ195.54,194.56,152.67,150.09,141.10,140.94,140.36,140.06,137.82,137.62,133.00,132.95,132.84,132.79,132.61,129.33,129.28,129.18,129.13,128.95,128.79,128.66,128.14,128.01,127.93,127.79,127.61,127.58,125.79,81.51,81.48,77.65,77.53,21.24,21.21.高分辨质谱(ESI,m/z):[M+H]+理论值:C24H22NO3S,404.1314;测量值:404.1311.
实施例10:
2-(4-氯苯基)-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-(4-氯苯基)-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物63mg,产率75%,dr=3:1。
主要异构体:1H NMR(400MHz,CDCl3)δ8.04–7.95(m,4H),7.55–7.40(m,6H),7.29–7.17(m,4H),7.09–7.00(m,1H),6.13(dd,J=10.2,1.0Hz,1H),5.69(s,1H),5.60(dd,J=3.5,1.0Hz,1H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.04–7.95(m,4H),7.55–7.40(m,6H),7.29–7.17(m,4H),7.09–7.00(m,1H),6.20(dd,J=10.2,1.9Hz,1H),5.82(dd,J=3.3,1.7Hz,1H),4.92(d,J=1.0Hz,1H).
13C NMR(151MHz,CDCl3)δ194.80,193.72,152.80,149.93,141.39,140.86,140.42,139.79,134.15,134.09,133.90,133.74,133.09,133.00,132.91,132.80,129.39,129.29,129.21,129.14,128.88,128.64,128.59,128.29,128.13,128.03,127.93,127.39,125.59,124.81,81.56,80.56,77.92,76.41.高分辨质谱(ESI,m/z):[M+H]+理论值:C23H19ClNO3S,424.0768;测量值:424.0755.
实施例11:
2-((叔丁基二甲基硅基)氧基)甲基)-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苯基亚砜亚胺(0.4mmol)和2-((叔丁基二甲基硅基)氧基)甲基)-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到无色液体产物46mg,产率50%,dr=6:1。
主要异构体:1H NMR(400MHz,CDCl3)δ8.07–8.00(m,4H),7.56–7.47(m,6H),6.96(dd,J=10.2,3.4Hz,1H),6.05(dd,J=10.2,0.9Hz,1H),5.65(dd,J=3.4,1.0Hz,1H),4.72(dd,J=4.6,2.6Hz,1H),4.03–3.91(m,2H),0.87–0.82(m,9H),0.05–0.03(m,6H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.07–8.00(m,4H),7.56–7.47(m,6H),7.03(dd,J=10.2,1.7Hz,1H),6.11(dd,J=16.6,6.1Hz,1H),5.79(d,J=2.9Hz,1H),4.38(t,J=2.2Hz,1H),4.03–3.91(m,2H),0.87–0.82(m,9H),0.05–0.03(m,6H).
13C NMR(101MHz,CDCl3)δ195.63,150.17,140.28,140.15,132.96,132.92,132.59,129.29,129.26,129.15,128.94,128.22,127.92,125.98,77.89,63.38,25.98,25.86,25.64,18.29,-5.42.高分辨质谱(ESI,m/z):[M+H]+理论值:C24H32NO4SSi,458.1816;测量值:458.1815.
实施例12:
6-((二甲基(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二甲基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到无色液体产物29mg,产率77%。
1H NMR(400MHz,CDCl3)δ6.94(dd,J=10.3,2.9Hz,1H),6.08(dd,J=10.3,1.5Hz,1H),5.64(dd,J=2.8,1.4Hz,1H),4.45(d,J=16.4Hz,1H),4.08(d,J=16.4Hz,1H),3.15(d,J=0.7Hz,3H),3.08(d,J=0.6Hz,3H).
13C NMR(101MHz,CDCl3)δ194.90,150.80,126.37,78.04,67.58,44.61,43.69.高分辨质谱(ESI,m/z):[M+H]+理论值:C7H12NO3S,190.0532;测量值:190.0535.
实施例13:
6-((二丁基(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二丁基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物32mg,产率58%。
1H NMR(400MHz,CDCl3)δ6.94(dd,J=10.3,2.9Hz,1H),6.08(dd,J=10.3,1.4Hz,1H),5.61(dd,J=2.6,1.3Hz,1H),4.47(d,J=16.4Hz,1H),4.07(d,J=16.4Hz,1H),3.25–2.96(m,4H),1.88–1.73(m,4H),1.52–1.41(m,4H),0.97(dd,J=7.4,6.7Hz,6H).13C NMR(101MHz,CDCl3)δ195.20,151.41,126.16,77.74,67.72,54.86,52.11,25.55,23.62,21.85,21.67,13.60,13.57.高分辨质谱(ESI,m/z):[M+Na]+理论值:C13H23NO3SNa,296.1291;测量值:296.1295.
实施例14:
6-((二苄基(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加二苄基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到无色液体产物35mg,产率52%。
1H NMR(400MHz,CDCl3)δ7.47–7.32(m,10H),6.74(dd,J=10.3,2.8Hz,1H),6.03(dd,J=10.3,0.9Hz,1H),5.44(s,1H),4.47(d,J=13.9Hz,1H),4.39(dd,J=18.7,15.2Hz,2H),4.15(s,2H),4.02(d,J=16.5Hz,1H).13C NMR(151MHz,CDCl3)δ195.27,151.36,131.49,131.03,129.18,129.05,128.96,128.65,128.60,126.79,126.04,78.05,67.94,62.11,58.53.高分辨质谱(ESI,m/z):[M+Na]+理论值:C19H19NO3SNa,364.0978;测量值:364.0980.
实施例15:
6-((甲基(oxo)(苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加甲基(亚氨基)(苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到无色液体产物33mg,产率66%,dr=1:1。
异构体一:1H NMR(400MHz,CDCl3)δ8.00–7.96(m,2H),7.69–7.56(m,3H),6.93(ddd,J=11.6,10.4,3.1Hz,1H),6.10–6.05(m,1H),5.45–5.40(m,1H),4.64(d,J=16.6Hz,1H),3.91(d,J=16.5Hz,1H),3.20(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.00–7.96(m,2H),7.69–7.56(m,3H),6.93(ddd,J=11.6,10.4,3.1Hz,1H),6.10–6.05(m,1H),5.45–5.40(m,1H),4.46(d,J=16.5Hz,1H),4.13–4.07(m,1H),3.15(s,3H).
13C NMR(101MHz,CDCl3)δ195.22,195.15,150.87,150.12,140.11,138.82,133.61,133.46,129.65,129.46,128.24,127.97,126.24,125.80,78.53,77.83,67.59,67.50,45.95,45.62.高分辨质谱(ESI,m/z):[M+H]+理论值:C12H14NO3S,252.0688;测量值:252.0694.
实施例16:
6-((乙基(oxo)(苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加乙基(亚氨基)(苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到无色液体产物25mg,产率48%,dr=1:1。
异构体一:1H NMR(400MHz,CDCl3)δ7.99–7.91(m,2H),7.70–7.56(m,3H),6.95(ddd,J=11.9,10.3,3.1Hz,1H),6.07(ddd,J=10.3,2.2,1.3Hz,1H),5.44(ddd,J=12.0,3.1,1.1Hz,1H),4.66(d,J=16.6Hz,1H),3.93(d,J=16.5Hz,1H),3.42–3.19(m,2H),1.32–1.21(m,3H).
异构体二:1H NMR(400MHz,CDCl3)δ7.99–7.91(m,2H),7.70–7.56(m,3H),6.95(ddd,J=11.9,10.3,3.1Hz,1H),6.07(ddd,J=10.3,2.2,1.3Hz,1H),5.44(ddd,J=12.0,3.1,1.1Hz,1H),4.48(d,J=16.5Hz,1H),4.09(d,J=16.6Hz,1H),3.42–3.19(m,2H),1.32–1.21(m,3H).
13C NMR(151MHz,CDCl3)δ195.41,195.29,151.21,150.34,138.13,136.67,133.55,133.42,129.55,129.35,129.03,128.82,126.09,125.67,78.49,77.84,67.62,67.52,51.79,51.44,7.58,7.01.高分辨质谱(ESI,m/z):[M+Na]+理论值:C13H15NO3SNa,288.0665;测量值:288.0670.
实施例17:
6-((4-(叔丁基)苯基)(oxo)(苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加(4-(叔丁基)苯基)(亚氨基)(苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物38mg,产率51%,dr=1:1。
异构体一:1HNMR(400MHz,CDCl3)δ8.05–7.89(m,4H),7.56–7.49(m,5H),7.02(t,J=3.2Hz,1H),6.10(s,1H),5.46(td,J=3.3,1.1Hz,1H),4.74(d,J=9.0Hz,1H),4.05(d,J=7.0Hz,1H),1.30(t,J=2.3Hz,9H).
异构体二:1H NMR(400MHz,CDCl3)δ8.05–7.89(m,4H),7.56–7.49(m,5H),7.00(t,J=3.2Hz,1H),6.07(s,1H),5.46(td,J=3.3,1.1Hz,1H),4.70(d,J=9.1Hz,1H),4.09(d,J=7.0Hz,1H),1.30(t,J=2.3Hz,9H).
13C NMR(151MHz,CDCl3)δ195.50,157.00,156.96,150.64,140.59,140.24,136.91,132.91,132.87,129.31,129.26,128.56,128.53,128.14,128.05,126.45,126.42,125.72,125.67,78.39,78.36,67.49,67.47,35.16,31.03.高分辨质谱(ESI,m/z):[M+H]+理论值:C21H24NO4S,370.1471;测量值:370.1469.
实施例18:
6-((甲基(oxo)(对甲苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(甲基)(对甲苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物29mg,产率54%,dr=1:1。
异构体一:1H NMR(400MHz,CDCl3)δ7.91–7.83(m,2H),7.40(t,J=8.1Hz,2H),6.99–6.90(m,1H),6.09(dd,J=4.7,1.2Hz,1H),5.41(dd,J=3.1,1.1Hz,1H),4.65(d,J=16.6Hz,1H),3.93(d,J=16.5Hz,1H),3.20(s,3H),2.46(t,J=3.9Hz,3H).
异构体二:1H NMR(400MHz,CDCl3)δ7.91–7.83(m,2H),7.40(t,J=8.1Hz,2H),6.99–6.90(m,1H),6.06(dd,J=4.7,1.2Hz,1H),5.41(dd,J=3.1,1.1Hz,1H),4.49(d,J=16.5Hz,1H),4.09(d,J=16.6Hz,1H),3.15(s,3H),2.46(t,J=3.9Hz,3H).
13C NMR(151MHz,CDCl3)δ195.31,195.23,151.01,150.22,144.67,144.48,136.78,135.54,130.29,130.10,128.31,128.04,126.16,125.69,78.56,77.81,77.30,77.09,76.88,67.55,67.45,45.94,45.68,21.56.高分辨质谱(ESI,m/z):[M+Na]+理论值:C13H15NO3SNa,288.0665;测量值:288.0670.
实施例19:
6-((4-甲氧基苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(4-甲氧苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物25mg,产率45%,dr=1:1。
异构体一:1H NMR(600MHz,CDCl3)δ7.88(dd,J=11.3,9.0Hz,2H),7.03(dd,J=10.1,9.1Hz,2H),6.94–6.89(m,1H),6.08–6.03(m,1H),5.38(dd,J=9.4,1.7Hz,1H),4.62(d,J=16.6Hz,1H),3.92(d,J=16.5Hz,1H),3.87(d,J=2.4Hz,3H),3.17(s,3H).
异构体二:1H NMR(600MHz,CDCl3)δ7.88(dd,J=11.3,9.0Hz,2H),7.03(dd,J=10.1,9.1Hz,2H),6.94–6.89(m,1H),6.08–6.03(m,1H),5.38(dd,J=9.4,1.7Hz,1H),4.47(d,J=16.5Hz,1H),4.09–4.05(m,1H),3.87(d,J=2.4Hz,3H),3.12(s,3H).
13C NMR(151MHz,CDCl3)δ195.35,195.25,163.75,163.67,151.15,150.27,130.54,130.20,126.18,125.68,114.88,114.67,78.53,77.84,67.63,67.46,55.77,55.72,46.16,45.94.高分辨质谱(ESI,m/z):[M+H]+理论值:C13H16NO4S,282.0794;测量值:282.0802.
实施例20:
6-((4-氯苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(4-氯苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物30mg,产率53%,dr=1:1。
异构体一:1HNMR(600MHz,CDCl3)δ7.90(dd,J=8.5,3.0Hz,2H),7.55(dd,J=13.9,8.6Hz,2H),6.90(ddd,J=15.5,10.3,3.0Hz,1H),6.08–6.05(m,1H),5.40(dd,J=10.8,1.5Hz,1H),4.59(d,J=16.6Hz,1H),3.91(d,J=16.5Hz,1H),3.19(s,3H).
异构体二:1H NMR(600MHz,CDCl3)δ7.90(dd,J=8.5,3.0Hz,2H),7.55(dd,J=13.9,8.6Hz,2H),6.90(ddd,J=15.5,10.3,3.0Hz,1H),6.08–6.05(m,1H),5.40(dd,J=10.8,1.5Hz,1H),4.41(d,J=16.5Hz,1H),4.08(d,J=16.6Hz,1H),3.13(s,3H).
13C NMR(151MHz,CDCl3)δ195.02,194.91,150.67,149.93,140.41,140.23,138.70,137.42,129.94,129.77,129.74,129.45,126.30,125.94,78.47,77.72,67.65,67.54,46.05,45.64.高分辨质谱(ESI,m/z):[M+Na]+理论值:C12H12ClNO3SNa,308.0118;测量值:308.0121.
实施例21:
6-((4-溴苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(4-溴苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物39mg,产率59%,dr=1:1。
异构体一:1H NMR(400MHz,CDCl3)δ7.84(dd,J=8.6,2.4Hz,2H),7.73(t,J=8.7Hz,2H),6.91(td,J=10.7,3.0Hz,1H),6.09(d,J=2.4Hz,1H),5.43(d,J=2.7Hz,1H),4.60(d,J=16.6Hz,1H),3.92(d,J=16.5Hz,1H),3.20(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ7.84(dd,J=8.6,2.4Hz,2H),7.73(t,J=8.7Hz,2H),6.91(td,J=10.7,3.0Hz,1H),6.07(d,J=2.3Hz,1H),5.41(d,J=2.5Hz,1H),4.42(d,J=16.5Hz,1H),4.12–4.07(m,1H),3.14(s,3H).
13C NMR(151MHz,CDCl3)δ195.03,194.92,150.68,149.93,139.29,138.01,132.95,132.75,129.86,129.52,128.96,128.80,126.33,125.97,78.49,77.74,67.69,67.57,46.05,45.65.高分辨质谱(ESI,m/z):[M+Na]+理论值:C12H12BrNO3SNa,351.9613;测量值:351.9620.
实施例22:
6-((3-甲氧基苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(3-甲氧基苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物33mg,产率58%,dr=1:1。
异构体一:1HNMR(600MHz,CDCl3)δ7.55–7.45(m,3H),7.20–7.12(m,1H),6.93(dd,J=10.3,3.0Hz,1H),6.08–6.06(m,1H),5.41(d,J=1.7Hz,1H),4.62(d,J=16.6Hz,1H),3.92(d,J=16.5Hz,1H),3.87(s,3H),3.19(s,3H).
异构体二:1H NMR(600MHz,CDCl3)δ7.55–7.45(m,3H),7.20–7.12(m,1H),6.90(dd,J=10.3,3.1Hz,1H),6.05(dd,J=4.6,0.9Hz,1H),5.39(d,J=1.8Hz,1H),4.46(d,J=16.5Hz,1H),4.08(d,J=16.6Hz,1H),3.86(s,3H),3.14(s,3H).
13C NMR(151MHz,CDCl3)δ195.24,195.24,195.14,160.41,160.21,150.88,150.09,141.24,139.90,130.71,130.49,126.22,125.76,120.26,119.85,119.82,112.93,112.87,78.61,77.78,67.59,67.49,55.78,55.72,45.86,45.60.高分辨质谱(ESI,m/z):[M+Na]+理论值:C13H15NO4SNa,304.0614;测量值:304.0619.
实施例23:
6-((3-溴苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(3-溴苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物42mg,产率64%,dr=1:1。
异构体一:1HNMR(400MHz,CDCl3)δ8.11(dt,J=3.6,1.8Hz,1H),7.90(ddd,J=7.9,3.3,1.8Hz,1H),7.77(dddd,J=9.0,8.0,1.8,0.9Hz,1H),7.46(dt,J=9.7,7.9Hz,1H),6.95–6.88(m,1H),6.09(dd,J=4.5,1.3Hz,1H),5.42(dt,J=2.9,1.4Hz,1H),4.59(d,J=16.6Hz,1H),4.09(d,J=16.6Hz,1H),3.20(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.11(dt,J=3.6,1.8Hz,1H),7.90(ddd,J=7.9,3.3,1.8Hz,1H),7.77(dddd,J=9.0,8.0,1.8,0.9Hz,1H),7.46(dt,J=9.7,7.9Hz,1H),6.95–6.88(m,1H),6.06(dd,J=4.5,1.3Hz,1H),5.42(dt,J=2.9,1.4Hz,1H),4.42(d,J=16.5Hz,1H),3.92(d,J=16.5Hz,1H),3.15(s,3H).
13C NMR(151MHz,CDCl3)δ195.00,194.92,150.51,149.86,142.38,140.96,136.68,136.49,131.21,131.10,130.92,130.90,126.68,126.44,126.33,125.97,123.66,123.40,78.48,77.65,67.56,46.03,45.56.高分辨质谱(ESI,m/z):[M+Na]+理论值:C12H12BrNO3SNa,351.9613;测量值:351.9620.
实施例24:
6-((2-甲氧基苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(2-甲氧基苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物25mg,产率44%,dr=1:1。
异构体一:1HNMR(400MHz,CDCl3)δ8.11–7.99(m,1H),7.68–7.57(m,1H),7.21–7.04(m,2H),6.94(dd,J=10.2,3.5Hz,1H),6.03(s,1H),5.41(d,J=3.3Hz,1H),4.67(d,J=16.6Hz,1H),3.99(s,3H),3.75(d,J=16.4Hz,1H),3.35(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.11–7.99(m,1H),7.68–7.57(m,1H),7.21–7.04(m,2H),6.83(dd,J=10.2,3.3Hz,1H),6.01(s,1H),5.19(d,J=3.0Hz,1H),4.45(d,J=16.4Hz,1H),4.04(d,J=16.6Hz,1H),3.98(s,3H),3.34(s,3H).
13C NMR(151MHz,CDCl3)δ195.70,195.58,156.90,156.63,150.62,150.08,135.70,135.30,131.97,130.75,126.03,125.55,121.25,120.96,112.20,112.07,79.04,76.90,67.20,66.70,56.10,56.06,43.69,43.43.高分辨质谱(ESI,m/z):[M+H]+理论值:C13H16NO4S,282.0794;测量值:282.0798.
实施例25:
6-((2-氯苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下,将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL),添加亚氨基(2-氯苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h,旋干后柱层析分离得到黄色液体产物34mg,产率60%,dr=1:1。
异构体一:1H NMR(400MHz,CDCl3)δ8.22(dt,J=16.8,5.0Hz,1H),7.65–7.43(m,3H),6.90(d,J=3.4Hz,1H),6.04(s,1H),5.42(d,J=3.4Hz,1H),4.63(d,J=16.7Hz,1H),3.83(d,J=16.6Hz,1H),3.38(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.22(dt,J=16.8,5.0Hz,1H),7.65–7.43(m,3H),6.88(d,J=3.4Hz,1H),6.01(s,1H),5.12(d,J=3.2Hz,1H),4.51(d,J=16.6Hz,1H),4.02(d,J=16.7Hz,1H),3.38(s,3H).
13C NMR(151MHz,CDCl3)δ195.27,195.19,150.01,149.51,138.14,134.89,134.85,134.43,133.24,132.31,132.15,132.08,131.97,131.73,128.11,127.67,126.18,125.73,79.16,77.00,67.37,67.36,43.44,43.23.高分辨质谱(ESI,m/z):[M+Na]+理论值:C12H12ClNO3SNa,308.0118;测量值:308.0119.
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
2.根据权利要求1所述的方法,其特征在于:R1、R2和R3中烷基为C1-C6的烷基、C3-C8的环烷基。
3.根据权利要求1或2所述的方法,其特征在于:所述R1、R2和R3中芳基为苯基或任选位置被Ra取代的苯基;所述Ra为C1-C6的烷基、C1-C6的烷氧基或卤素。
5.根据权利要求3所述的方法,其特征在于:反应温度为0-60℃,优选为20-30℃,反应时间为12-72h。
6.根据权利要求3所述的方法,其特征在于:式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的摩尔比为1:1-10:1。
7.根据权利要求6所述的方法,其特征在于:式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的摩尔比为2:1。
8.根据权利要求3所述的方法,其特征在于:所述的(PhO)2P(O)OH的用量为式II所示二氢吡喃酮的20mol%。
9.根据权利要求3所述的方法,其特征在于:所述的有机溶剂为乙腈、甲苯、氯仿、二氯甲烷、1,2-二氯乙烷、四氢呋喃、丙酮中的一种或两种以上混合。
10.根据权利要求3所述的方法,其特征在于:所述的有机溶剂为氯仿或二氯甲烷。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111209332.7A CN114133367B (zh) | 2021-10-18 | 2021-10-18 | 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111209332.7A CN114133367B (zh) | 2021-10-18 | 2021-10-18 | 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114133367A true CN114133367A (zh) | 2022-03-04 |
CN114133367B CN114133367B (zh) | 2023-03-21 |
Family
ID=80394215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111209332.7A Active CN114133367B (zh) | 2021-10-18 | 2021-10-18 | 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114133367B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016013633A1 (ja) * | 2014-07-24 | 2016-01-28 | 日本曹達株式会社 | アリールオキシ化合物および有害生物防除剤 |
WO2018130174A1 (zh) * | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
CN109180565A (zh) * | 2018-09-21 | 2019-01-11 | 大连理工大学 | 一种新型6-烷氧基-2h-二氢吡啶-3酮的制备方法 |
CN109232391A (zh) * | 2018-09-21 | 2019-01-18 | 大连理工大学 | 一种新型6-巯基-2h-二氢吡啶-3酮的制备方法 |
TW201912641A (zh) * | 2017-09-08 | 2019-04-01 | 印度商Pi工業公司 | 新型殺真菌雜環化合物 |
CN112409345A (zh) * | 2020-11-20 | 2021-02-26 | 大连理工大学 | 一种新型二氢吡喃酮基香豆素类化合物的制备方法 |
-
2021
- 2021-10-18 CN CN202111209332.7A patent/CN114133367B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016013633A1 (ja) * | 2014-07-24 | 2016-01-28 | 日本曹達株式会社 | アリールオキシ化合物および有害生物防除剤 |
WO2018130174A1 (zh) * | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
TW201912641A (zh) * | 2017-09-08 | 2019-04-01 | 印度商Pi工業公司 | 新型殺真菌雜環化合物 |
CN109180565A (zh) * | 2018-09-21 | 2019-01-11 | 大连理工大学 | 一种新型6-烷氧基-2h-二氢吡啶-3酮的制备方法 |
CN109232391A (zh) * | 2018-09-21 | 2019-01-18 | 大连理工大学 | 一种新型6-巯基-2h-二氢吡啶-3酮的制备方法 |
CN112409345A (zh) * | 2020-11-20 | 2021-02-26 | 大连理工大学 | 一种新型二氢吡喃酮基香豆素类化合物的制备方法 |
Non-Patent Citations (3)
Title |
---|
SANJEEVA R. GUPPI 等: "De Novo Asymmetric Synthesis of Homoadenosine via a Palladium-Catalyzed N-Glycosylation", 《ORG. LETT.》 * |
YI-ZHU ZHANG 等: "Organocatalytic C3-functionalization of indolizines: synthesis of biologically important indolizine derivatives", 《ORG. BIOMOL. CHEM.》 * |
孙鑫浩 等: "布朗斯特酸催化合成亚砜亚胺基二氢吡喃酮类衍生物", 《有机化学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114133367B (zh) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS196376B2 (en) | Method for the stereoselective production of optical isomers of hexahydrodibenzopyranone derivatives | |
Meshram et al. | Boric acid promoted an efficient and practical synthesis of fused pyrimidines in aqueous media | |
Pei et al. | DABCO-catalyzed regioselective cyclization reactions of β, γ-unsaturated α-ketophosphonates or β, γ-unsaturated α-ketoesters with allenic esters | |
EP4186915A1 (en) | Method for synthesizing c-nucleoside compound | |
CN111763148B (zh) | 一种含三氟甲基的炔基环戊烯衍生物及其制备方法和应用 | |
Ghosh et al. | A ketal-tethered RCM strategy toward the synthesis of spiroketal related natural products | |
CN110156796B (zh) | 异恶唑拼接3,3’-硫代吡咯啉酮双螺环氧化吲哚化合物及其制备方法及应用 | |
EP2537839B1 (en) | B-dihydrofuran deriving compound, method for producing b-dihydrofuran deriving compound or b-tetrahydrofuran deriving compound, b -glycoside compound, method for producing b-glycoside compound, and method for producing 4'-ethynyl d4t and analogue compounds thereof | |
CN114133367B (zh) | 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 | |
Wu et al. | In (iii)-Catalyzed tandem reaction of chromone-derived Morita–Baylis–Hillman alcohols with amines | |
CN111646964B (zh) | 一种碱催化的合成2h-吡喃-2-酮衍生物新方法 | |
EP2611811B1 (en) | New process for preparing cyclolignans | |
CN108440526B (zh) | 一种手性巴比妥螺四氢喹啉类化合物及制备方法 | |
Pan et al. | Dioxane-involving reaction for the synthesis of 3-aryl-1-(2-(vinyloxy) ethoxy) isoquinolines catalyzed by AgOTf | |
US5481008A (en) | Process for the preparation of optically active compounds | |
Lemus et al. | Lewis acid catalyzed enlargement of cyclic β‐alkoxyenals and one‐pot synthesis of polyfunctional enoxysilanes derived from aucubin with trimethylsilyldiazomethane | |
CN113372353A (zh) | 一种二氟烷基化的二氢呋喃喹啉酮衍生物及其制备方法 | |
EP3984982A1 (en) | Method for producing morphinan derivative | |
Svĕtlík et al. | Three-component reaction and organocatalysis in one: Synthesis of densely substituted 4-aminochromanes | |
CN107445914B (zh) | 一种2,2,5-三取代1,3,4噁二唑衍生物及其合成方法 | |
Otero et al. | Preliminary studies on the synthesis of rancinamycins from nitrosugars: first total synthesis of (3S, 4S, 5S, 6R)-5-benzyloxy-6-hydroxy-3, 4-(isopropylidendioxy)-cyclohex-1-enecarbaldehyde | |
CN111560022A (zh) | 四氢苯并呋喃[3,2-d]嘧啶类衍生物及其制备方法及应用 | |
Takaki et al. | NHC-catalyzed reaction of enals with unactivated enones: substituent effect on the formation of 1: 1 and 1: 2 adducts | |
US6191279B1 (en) | Dipyrano-quinolinones useful as anti viral agents and a process for preparing the same | |
Rai et al. | Sn-PILC: A novel Efficient and Recyclable Catalyst for One-pot Three Component Povarov’s Inverse-electron-demand Hetero Diels-Alder Reaction for a Facile Synthesis of Tetrahydropyranoquinoline Derivatives under Neat Conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |